Achilles Therapeutics plc
ACHL
$1.48
$0.010.68%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -7.95% | -11.25% | -16.96% | -19.46% | -27.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.78% | 3.36% | 0.19% | 5.58% | -3.43% |
| Operating Income | -0.78% | -3.36% | -0.19% | -5.58% | 3.43% |
| Income Before Tax | 11.55% | 10.30% | 10.08% | 2.66% | -14.98% |
| Income Tax Expenses | 1,696.30% | 406.52% | 202.86% | 342.34% | -59.09% |
| Earnings from Continuing Operations | 10.94% | 9.76% | 9.67% | 2.12% | -14.91% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 10.94% | 9.76% | 9.67% | 2.12% | -14.91% |
| EBIT | -0.78% | -3.36% | -0.19% | -5.58% | 3.43% |
| EBITDA | -0.37% | -2.60% | 1.35% | -4.37% | 4.61% |
| EPS Basic | 12.13% | 11.08% | 11.16% | 3.94% | -13.82% |
| Normalized Basic EPS | 3.56% | 1.74% | 1.80% | -6.05% | -3.05% |
| EPS Diluted | 12.13% | 11.08% | 11.16% | 3.94% | -13.82% |
| Normalized Diluted EPS | 3.56% | 1.74% | 1.80% | -6.05% | -3.05% |
| Average Basic Shares Outstanding | 1.28% | 1.53% | 1.75% | 1.95% | 1.06% |
| Average Diluted Shares Outstanding | 1.28% | 1.53% | 1.75% | 1.95% | 1.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
